Acute herpes zoster: Difference between revisions
No edit summary |
m (Rossdonaldson1 moved page Herpes zoster to Acute herpes zoster) |
||
| (73 intermediate revisions by 19 users not shown) | |||
| Line 1: | Line 1: | ||
== Background | ==Background== | ||
[[File:Dermatoms alt.png|thumb|Sensory dermatomes by spinal level.]] | |||
*Also known as shingles | |||
*Caused by [[varicella zoster virus]] (VZV; also known as Human Herpes Virus 3) causing [[Varicella]] (chicken pox) and later zoster (shingles) | |||
*Virus is dormant in dorsal root ganglion and reactivates causing characteristic vesiculopapular rash in dermatomal distribution | |||
*Occurs once immunity to virus declines (elderly, immunosuppressed, post transplant, HIV) | |||
===Prevention=== | |||
* | *Patient is contagious until lesions are crusted over | ||
* | *Consider varicella-zoster immunoglobulin to immunosupressed, pregnant, neonate contacts | ||
*Zoster vaccination if >60 | |||
{{Herpes viruses}} | |||
== Clinical Features | ==Clinical Features== | ||
[[File:Zoster.jpeg|thumb|Herpes Zoster]] | |||
*Prodrome: Headache, malaise, photophobia | [[File:Shingles.jpg|thumb|Herpes Zoster]] | ||
*Antecedent | *Prodrome: [[Headache]], [[Weakness|malaise]], photophobia | ||
*Maculopapular rash progresses to vesicles | *Antecedent [[pruritus]], [[paresthesia]], pain to dermatome 2-3 days prior to rash | ||
*Maculopapular [[rash]] (see below) progresses to vesicles, may coalesce to bullae, in dermatomal distribution lasting 10-15 days | |||
*Does not cross midline | *Does not cross midline | ||
*Typically affects chest/face | *Typically affects chest/face | ||
* | *Lumbar and sacral dermatomes may display skin sparing between the feet and groin | ||
*V3 involvement can present initially as dental pain | |||
[[File:Herpes Zoster.jpg|thumb]] | |||
* | |||
== | ==Differential Diagnosis== | ||
{{Bullous rashes DDX}} | |||
{{VZV types}} | |||
==Evaluation== | |||
===Workup=== | |||
*Generally a clinical diagnosis | |||
*May consider viral Culture, antigen, PCR of vesicle fluid | |||
< | ===Evaluation=== | ||
*Confirm that the patient does not have: | |||
**[[Herpes zoster ophthalmicus]] | |||
**[[Herpes zoster oticus]] (Ramsay Hunt syndrome) | |||
*Consider further evaluation for immunocompromized state (may be initial presentation of [[HIV]]) if: | |||
**Disseminated | |||
***For skin, disseminated is defined as more than 20 lesions outside the primary and adjacent dermatomes<ref>Bolognia, J. L., Schaffer, J. V., & Cerroni, L. (n.d.). Dermatology: 2-Volume Set. Elsevier.3 or more dermatomes affected.</ref> | |||
***Can also disseminate to other organs including liver, lung, and brain. | |||
**Atypical illness/severe disease | |||
*In immunocompromised patients consider further evaluation for: | |||
**Pneumonitis | |||
**[[Hepatitis]] | |||
**[[Encephalitis]] | |||
== | ==Management== | ||
===[[Analgesia]]=== | |||
*Analgesia is very important and should be prescribed along with an antiviral | |||
*Consider [[lidocaine]] patch, [[NSAIDS]], oral [[opioids]], or [[gabapentin]] | |||
*[[Diphenhydramine]] and [[ranitidine]] for itch/pain | |||
* | ===[[Antivirals]]=== | ||
* | *Reduces risk/duration of [[postherpetic neuralgia]] with dosing based on immune status and time course of disease | ||
* | *Not effective in treating postherpetic neuralgia once it has developed | ||
'''Immunocompetent patients:''' | |||
*[[Acyclovir]] 800mg PO 5x/day x 7d if <72hr of onset of rash or >72hr if new vesicles present/developing<ref>Cohen, J. Herpes Zoster. N Engl J Med 2013; 369:255-263. DOI: 10.1056/NEJMcp1302674</ref> | |||
*[[Valacyclovir]] (can also be given but is generally more expensive than acyclovir) | |||
**1g PO q8hrs (CrCl normal) | |||
**1g PO q12hrs (CrCl 30-49 mL/min) | |||
**1g PO q24hrs (CrCl 10-29 mL/min( | |||
**500mg q24hrs PO (CrCl < 10ml/min) | |||
'''Immunosuppressed patients:''' | |||
*Antiviral therapy should be given regardless of the time of onset of rash | |||
*[[Acyclovir]] 10mg/kg IV q8h OR 800mg PO 5x/day x 7d or [[Foscarnet]] for acyclovir-resistant VZV, disseminated zoster, CNS involvement, ophthalmic involvement, advanced AIDS, or recent transplant | |||
*Isolation precautions | |||
**Disseminated zoster requires airborne precautions | |||
< | ===[[Glucocorticoids]]=== | ||
*Steroids ''not'' shown to be beneficial<ref>He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008.</ref> | |||
== | ==Disposition== | ||
*Admit for disseminated VZ, CNS involvement, severely immunosuppressed | |||
*Healing of lesions may take 4 or more weeks<ref>Sampathkumar P, et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84(3):274–280.</ref> | |||
[[ | ==Complications== | ||
*[[Postherpetic neuralgia]] (risk increases with age) | |||
*[[Cellulitis]] | |||
*[[Impetigo]] | |||
*[[Necrotizing Fasciitis]] | |||
*[[SIADH]] | |||
== | ==See Also== | ||
*[[Postherpetic neuralgia]] | |||
*[[Herpes zoster ophthalmicus]] | |||
*[[Herpes zoster oticus]] (Ramsay Hunt syndrome) | |||
*[[Generalized rashes]] | |||
==References== | |||
<references/> | |||
[[Category:ID]] | [[Category:ID]] | ||
Latest revision as of 19:07, 29 January 2025
Background
- Also known as shingles
- Caused by varicella zoster virus (VZV; also known as Human Herpes Virus 3) causing Varicella (chicken pox) and later zoster (shingles)
- Virus is dormant in dorsal root ganglion and reactivates causing characteristic vesiculopapular rash in dermatomal distribution
- Occurs once immunity to virus declines (elderly, immunosuppressed, post transplant, HIV)
Prevention
- Patient is contagious until lesions are crusted over
- Consider varicella-zoster immunoglobulin to immunosupressed, pregnant, neonate contacts
- Zoster vaccination if >60
Herpes Virus Types
- HHV-1: Herpes Simplex Virus-1
- HHV-2: Herpes Simplex Virus-2
- Herpes B virus
- Varicella zoster virus
- Varicella (Chickenpox)
- Herpes zoster (Shingles)
- Herpes zoster ophthalmicus
- Herpes zoster oticus (Ramsay Hunt syndrome)
- HHV-6 (Roseola infantum)
- HHV-8 (Kaposi’s sarcoma)
- Epstein-Barr virus
- Cytomegalovirus
Clinical Features
- Prodrome: Headache, malaise, photophobia
- Antecedent pruritus, paresthesia, pain to dermatome 2-3 days prior to rash
- Maculopapular rash (see below) progresses to vesicles, may coalesce to bullae, in dermatomal distribution lasting 10-15 days
- Does not cross midline
- Typically affects chest/face
- Lumbar and sacral dermatomes may display skin sparing between the feet and groin
- V3 involvement can present initially as dental pain
Differential Diagnosis
Vesiculobullous rashes
Febrile
- Diffuse distribution
- Varicella (chickenpox)
- Smallpox
- Monkeypox
- Disseminated gonococcal disease
- DIC
- Purpural fulminans
- Localized distribution
Afebrile
- Diffuse distribution
- Bullous pemphigoid
- Drug-Induced bullous disorders
- Pemphigus vulgaris
- Phytophotodermatitis
- Erythema multiforme major
- Bullous impetigo
- Localized distribution
- Contact dermatitis
- Herpes zoster (shingles)
- Dyshidrotic eczema
- Burn
- Dermatitis herpetiformis
- Erythema multiforme minor
- Poison Oak, Ivy, Sumac dermatitis
- Bullosis diabeticorum
- Bullous impetigo
- Folliculitis
Varicella zoster virus
- Varicella (Chickenpox)
- Herpes zoster (Shingles)
- Herpes zoster ophthalmicus
- Herpes zoster oticus (Ramsay Hunt syndrome)
Evaluation
Workup
- Generally a clinical diagnosis
- May consider viral Culture, antigen, PCR of vesicle fluid
Evaluation
- Confirm that the patient does not have:
- Herpes zoster ophthalmicus
- Herpes zoster oticus (Ramsay Hunt syndrome)
- Consider further evaluation for immunocompromized state (may be initial presentation of HIV) if:
- Disseminated
- For skin, disseminated is defined as more than 20 lesions outside the primary and adjacent dermatomes[1]
- Can also disseminate to other organs including liver, lung, and brain.
- Atypical illness/severe disease
- Disseminated
- In immunocompromised patients consider further evaluation for:
- Pneumonitis
- Hepatitis
- Encephalitis
Management
Analgesia
- Analgesia is very important and should be prescribed along with an antiviral
- Consider lidocaine patch, NSAIDS, oral opioids, or gabapentin
- Diphenhydramine and ranitidine for itch/pain
Antivirals
- Reduces risk/duration of postherpetic neuralgia with dosing based on immune status and time course of disease
- Not effective in treating postherpetic neuralgia once it has developed
Immunocompetent patients:
- Acyclovir 800mg PO 5x/day x 7d if <72hr of onset of rash or >72hr if new vesicles present/developing[2]
- Valacyclovir (can also be given but is generally more expensive than acyclovir)
- 1g PO q8hrs (CrCl normal)
- 1g PO q12hrs (CrCl 30-49 mL/min)
- 1g PO q24hrs (CrCl 10-29 mL/min(
- 500mg q24hrs PO (CrCl < 10ml/min)
Immunosuppressed patients:
- Antiviral therapy should be given regardless of the time of onset of rash
- Acyclovir 10mg/kg IV q8h OR 800mg PO 5x/day x 7d or Foscarnet for acyclovir-resistant VZV, disseminated zoster, CNS involvement, ophthalmic involvement, advanced AIDS, or recent transplant
- Isolation precautions
- Disseminated zoster requires airborne precautions
Glucocorticoids
- Steroids not shown to be beneficial[3]
Disposition
- Admit for disseminated VZ, CNS involvement, severely immunosuppressed
- Healing of lesions may take 4 or more weeks[4]
Complications
- Postherpetic neuralgia (risk increases with age)
- Cellulitis
- Impetigo
- Necrotizing Fasciitis
- SIADH
See Also
- Postherpetic neuralgia
- Herpes zoster ophthalmicus
- Herpes zoster oticus (Ramsay Hunt syndrome)
- Generalized rashes
References
- ↑ Bolognia, J. L., Schaffer, J. V., & Cerroni, L. (n.d.). Dermatology: 2-Volume Set. Elsevier.3 or more dermatomes affected.
- ↑ Cohen, J. Herpes Zoster. N Engl J Med 2013; 369:255-263. DOI: 10.1056/NEJMcp1302674
- ↑ He L, Zhang D, Zhou M, Zhu C. Corticosteroids for preventing postherpetic neuralgia. Cochrane Database Syst Rev. 2008.
- ↑ Sampathkumar P, et al. Herpes zoster (shingles) and postherpetic neuralgia. Mayo Clin Proc. 2009; 84(3):274–280.
